2010•BMJ Case ReportsOpen access

Ischaemic stroke in a patient on sunitinib: Figure 1

M. Lonergan, F. Kellehar, Raymond McDermott, Rónán Collins

Abstract

Concerns have been raised about possible theoretical risk of thrombosis and bleeding with sunitinib (anti-vascular endothelial cell growth factor agent) therapy used for treatment of metastatic renal cell carcinoma. We present the first case of stroke in an older man with metastatic renal cell carcinoma, on sunitinib therapy.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Sunitinib, Medicine, Renal cell carcinoma, Stroke (engine), Thrombosis, Internal medicine, Vascular endothelial growth factor, Oncology